A biopharmaceutical drug used to treat rheumatoid arthritis.

Trade name Kineret

It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein.

US: B- No risk in non-human studies.

Subcutaneous agent.

Bioavailability 95%. Metabolism is predominantly renal.

Elimination half-life 4-6 hrs.

It is used as a second line treatment to manage symptoms of rheumatoid arthritis after treatment with a disease-modifying antirheumatic drug (DMARD) has failed.

It can be used in combination with some DMARDs.

Appears to be safe in animal studies.

It should not be used in people who have active infections or latent turberculosis, who have low white blood cells counts, or who are taking TNF inhibitors.

More than ten percent have injection site reactions, headaches, and have increased levels of cholesterol in their blood.

1-10% of patients have severe infections, decreased white blood cells, or decreased platelets.

It differs from the sequence of Interleukin 1 receptor antagonist by one methionine added to its N-terminus.

Anakinra/tocilizumab is used for the treatment of Adult-Onset Still’s Disease refractory to second-line therapy.

Leave a Reply

Your email address will not be published.